APA (7th ed.) Citation

Shuang Chen, Caihua Li, Caihua Li, Zeng Tu, Tao Cai, Xinying Zhang, . . . Dan Wang. (2024). Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Shuang Chen, et al. Off-label Use of Baricitinib Improves Moderate and Severe Atopic Dermatitis in China Through Inhibiting MAPK and PI3K/Akt/mTOR Pathway via Targeting JAK-STAT Signaling of CD4+ Cells. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Shuang Chen, et al. Off-label Use of Baricitinib Improves Moderate and Severe Atopic Dermatitis in China Through Inhibiting MAPK and PI3K/Akt/mTOR Pathway via Targeting JAK-STAT Signaling of CD4+ Cells. Frontiers Media S.A., 2024.